[en] [en] INTRODUCTION: Guidelines for antiplatelet therapy administration, during emergent stenting for extra-cranial internal carotid artery (EC-ICA) occlusion in the setting of acute ischemic stroke (AIS) are lacking. Different antiplatelet regimen are used in association to endovascular therapy (EVT) for the treatment of EC-ICA lesions. We aimed to compare the clinical and radiological effects of three intravenous antiplatelet agents used during emergent EC-ICA stenting.
MATERIAL AND METHODS: Clinical data were collected from January 2015 to December 2019 in a monocentric prospective registry of AIS patients treated by EVT. All patients who underwent emergent EC-ICA stenting were sorted regarding the intravenous antiplatelet agent used during the procedure.
RESULTS: Among 218 patients treated by EVT for an EC-ICA occlusion of the anterior circulation during the study period, 70 underwent an emergent stenting of the EC-ICA. 60 were included in the present study, 9 received intravenous (IV) Cangrelor, 8 IV abciximab and 43 Aspirin. The rate of favorable neurological outcome, defined as modified Rankin Scale (mRS) ≤ 2 at three months were better in the Cangrelor and Aspirin groups (66,7% and 58,1%, respectively) than in the Abciximab group (37,5%), as well as, the rate of any intracranial ICH (22,2% and 37,2% vs 62,5%). The rate of acute stent reocclusion was similar between groups.
CONCLUSION: When used as a rescue treatment during emergent stenting of EC-ICA, Cangrelor and Aspirin present a better safety profile than Abciximab, with less intracranial hemorrhages and a higher rate of good clinical outcome. Additional studies are needed to confirm these findings.
Disciplines :
Neurology
Author, co-author :
Delvoye, François ; Université de Liège - ULiège > Département des sciences cliniques
Maier, Benjamin; Interventional Neuroradiology Department, Rothschild Foundation Hospital, Paris, France, Laboratory of Vascular Translational Science, U1148 INSERM, Université de Paris, 46 rue Henri Huchard 75018 Paris, France. Electronic address: bmaier@for.paris
Escalard, Simon ; Interventional Neuroradiology Department, Rothschild Foundation Hospital, Paris, France. Electronic address: sescalard@for.paris
Labreuche, Julien ; University of Lille, CHU Lille, EA 2694 - Santé Publique: Épidémiologie et Qualité des Soins, F-59000 Lille, France. Electronic address: julien.labreuche.chru@gmail.com
Thion, Laurie-Anne; Anesthesiology Department, Rothschild Foundation Hospital, Paris, France. Electronic address: lathion@for.paris
Aknouche, Soufiane ; Clinical Research Unit, Rothschild Foundation Hospital, Paris, France. Electronic address: saknouche@for.paris
Hebert, Solène; Interventional Neuroradiology Department, Rothschild Foundation Hospital, Paris, France. Electronic address: shebert@for.paris
Redjem, Hocine; Interventional Neuroradiology Department, Rothschild Foundation Hospital, Paris, France. Electronic address: hredjem@for.paris
Smajda, Stanislas ; Interventional Neuroradiology Department, Rothschild Foundation Hospital, Paris, France. Electronic address: ssmajda@for.paris
Ciccio, Gabriele; Interventional Neuroradiology Department, Rothschild Foundation Hospital, Paris, France. Electronic address: gciccio@for.paris
Allard, Julien; Interventional Neuroradiology Department, Rothschild Foundation Hospital, Paris, France. Electronic address: jallard@for.paris
Sabben, Candice; Neurology Department, Rothschild Foundation Hospital, Paris, France. Electronic address: csabben@for.paris
Obadia, Michael; Neurology Department, Rothschild Foundation Hospital, Paris, France. Electronic address: mobadia@for.paris
Blanc, Raphael; Interventional Neuroradiology Department, Rothschild Foundation Hospital, Paris, France, Laboratory of Vascular Translational Science, U1148 INSERM, Université de Paris, 46 rue Henri Huchard 75018 Paris, France. Electronic address: rblanc@for.paris
Piotin, Michel; Interventional Neuroradiology Department, Rothschild Foundation Hospital, Paris, France, Laboratory of Vascular Translational Science, U1148 INSERM, Université de Paris, 46 rue Henri Huchard 75018 Paris, France. Electronic address: mpiotin@for.paris
Desilles, Jean-Philippe; Interventional Neuroradiology Department, Rothschild Foundation Hospital, Paris, France, Laboratory of Vascular Translational Science, U1148 INSERM, Université de Paris, 46 rue Henri Huchard 75018 Paris, France, Université de Paris, France. Electronic address: jpdesilles@for.paris
Mazighi, Mikael; Interventional Neuroradiology Department, Rothschild Foundation Hospital, Paris, France, Laboratory of Vascular Translational Science, U1148 INSERM, Université de Paris, 46 rue Henri Huchard 75018 Paris, France, Université de Paris, France, FHU Neurovasc, France. Electronic address: mmazighi@for.paris
Jadhav, A.P., Zaidat, O.O., Liebeskind, D.S., et al. Emergent Management of Tandem Lesions in Acute Ischemic Stroke. Stroke 50:2 (2019), 428–433.
Jadhav, A., Panczykowski, D., Jumaa, M., et al. Angioplasty and stenting for symptomatic extracranial non-tandem internal carotid artery occlusion. J Neurointerv Surg 10:12 (2018), 1155–1160.
Zhu, F., Anadani, M., Labreuche, J., et al. Impact of antiplatelet therapy during endovascular therapy for tandem occlusions: A collaborative pooled analysis. Stroke 51:5 (2020), 1522–1529.
Mauri, L., Kereiakes, D.J., Yeh, R.W., et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371:23 (2014), 2155–2166.
Pop, R., Zinchenko, I., Quenardelle, V., et al. Predictors and clinical impact of delayed stent thrombosis after thrombectomy for acute stroke with tandem lesions. AJNR Am J Neuroradiol 40:3 (2019), 533–539.
Markus, H.S., Droste, D.W., Kaps, M., et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation 111:17 (2005), 2233–2240.
Heck, D.V., Brown, M.D., Carotid stenting and intracranial thrombectomy for treatment of acute stroke due to tandem occlusions with aggressive antiplatelet therapy may be associated with a high incidence of intracranial hemorrhage. J Neurointerv Surg 7:3 (2015), 170–175.
Hacke, W., Kaste, M., Bluhmki, E., et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359:13 (2008), 1317–1329.
Zhu, F., Labreuche, J., Haussen, D.C., et al. Hemorrhagic transformation after thrombectomy for tandem occlusions. Stroke 50:2 (2019), 516–519.
Investigators, E., Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 352:9122 (1998), 87–92.
Eckert, B., Koch, C., Thomalla, G., et al. Aggressive therapy with intravenous abciximab and intra-arterial rtPA and additional PTA/stenting improves clinical outcome in acute vertebrobasilar occlusion: combined local fibrinolysis and intravenous abciximab in acute vertebrobasilar stroke treatment (FAST): results of a multicenter study. Stroke 36:6 (2005), 1160–1165.
Gruber, P., Hlavica, M., Berberat, J., et al. Acute administration of tirofiban versus aspirin in emergent carotid artery stenting. Interv Neuroradiol 25:2 (2019), 219–224.
Al-Mufti, F., Amuluru, K., Manning, N.W., et al. Emergent carotid stenting and intra-arterial abciximab in acute ischemic stroke due to tandem occlusion. Br J Neurosurg 31:5 (2017), 573–579.
Kapadia, S.R., Bajzer, C.T., Ziada, K.M., et al. Initial experience of platelet glycoprotein IIb/IIIa inhibition with abciximab during carotid stenting: a safe and effective adjunctive therapy. Stroke 32:10 (2001), 2328–2332.
Qureshi, A.I., Saad, M., Zaidat, O.O., et al. Intracerebral hemorrhages associated with neurointerventional procedures using a combination of antithrombotic agents including abciximab. Stroke 33:7 (2002), 1916–1919.
Adams, H.P. Jr., Effron, M.B., Torner, J., et al. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke 39:1 (2008), 87–99.
Wholey, M.H., Wholey, M.H., Eles, G., et al. Evaluation of glycoprotein IIb/IIIa inhibitors in carotid angioplasty and stenting. J Endovasc Ther 10:1 (2003), 33–41.
Bhatt, D.L., Stone, G.W., Mahaffey, K.W., et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 368:14 (2013), 1303–1313.
Akers, W.S., Oh, J.J., Oestreich, J.H., et al. Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist. J Clin Pharmacol 50:1 (2010), 27–35.
Mascelli, M.A., Lance, E.T., Damaraju, L., et al. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 97:17 (1998), 1680–1688.
Godier, A., Mesnil, M., Mesmay, M.D., et al. Bridging antiplatelet therapy with cangrelor in patients with recent intracranial stenting undergoing invasive procedures: a prospective case series. Br J Anaesth 123:1 (2019), e2–e5.
Aguilar-Salinas, P., Agnoletto, G.J., Brasiliense, L.B.C., et al. Safety and efficacy of cangrelor in acute stenting for the treatment of cerebrovascular pathology: preliminary experience in a single-center pilot study. J Neurointerv Surg 11:4 (2019), 347–351.
Zinkstok, S.M., Roos, Y.B., Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial. Lancet 380:9843 (2012), 731–737.
